Page last updated: 2024-11-08

16-methylcyprenorphine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

16-methylcyprenorphine: RN given refers to (5alpha,7alpha,16S)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162443
SCHEMBL ID1239514
MeSH IDM0145807

Synonyms (9)

Synonym
40994-80-7
16-methylcyprenorphine
rx-8008-m
rx 8008m
6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-methoxy-alpha,alpha,16-trimethyl-, (5alpha,7alpha,16s)-
SCHEMBL1239514
(1r,2s,4s,14r,15r,19r)-5-(cyclopropylmethyl)-19-(2-hydroxypropan-2-yl)-15-methoxy-4-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol
17-(cyclopropylmethyl)-7-(2-hydroxypropan-2-yl)-6-methoxy-16-methyl-4,5-epoxy-6,14-ethenomorphinan-3-ol
DTXSID30961372

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Both antagonists produced large shifts in the dose-response curves to the mu-agonists, morphine and fentanyl, confirming their mu-antagonist activity."( Reversal by beta-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig.
Birch, PJ; Hayes, AG, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (50.00)18.7374
1990's6 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.81 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]